Search for: "Pfizer, Inc." Results 901 - 920 of 1,512
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Jul 2010, 7:57 pm
Recently, Pfizer Inc voluntarily withdrew the drug Mylotarg (gemtuzumab ozogamicin) from the U.S. market. [read post]
10 Jul 2010, 5:00 am by Michael Silverman
Johnson is currently a director of Intuit Inc., Pfizer Inc., and Visa Inc.; she was formerly Vice Chairman of The Goldman Sachs Group. [read post]
9 Jul 2010, 3:57 pm by Editors
Counsel – Pfizer Inc., Pearl River, NY Formalities Officer (Patent) – Novartis Institutes of Biomedical Research, Emeryville (SF Bay Area), CA Senior Corporate Counsel – J. [read post]
8 Jul 2010, 5:00 am by Anapol Schwartz
West-Ward Pharmaceuticals, Pfizer, and Sagent Pharmaceuticals all recalled batches of Ondansetron prepared by Claris LifeSciences, Inc. after it was discovered that the batches were not sterile because they had not been prepared properly. [read post]
6 Jul 2010, 8:00 am by Michael Silverman
Gray holds the most current director positions as Co-Chairman of GrayLoeffler, LLC, and a director at Dell Computer Corporation (since 2000), Pfizer, Inc. [read post]
1 Jul 2010, 6:30 am by Peter Rost
Senator Charles Grassley asked 16 drugmakers, including Pfizer Inc., AstraZeneca Plc and Eli Lilly & Co., to reveal how they treat whistleblowers who file complaints under the False Claims Act.Grassley, an Iowa Republican, sent letters June 28 that posed eight questions such as how companies notify employees of the law, how they treat whistleblowers and what changes they have made in response to a 2009 law extending anti-retaliation protections. [read post]
30 Jun 2010, 9:01 am by Matthew Scarola
The Court declined to grant certiorari in Pfizer, Inc. v. [read post]
30 Jun 2010, 5:52 am
(Patent Docs) Sutent (Sunitinib) – US: Patent infringement complaint filed following a Paragraph IV certification: Pfizer Inc. et al. v. [read post]
29 Jun 2010, 6:01 pm by Duncan
(Patent Docs) Sutent (Sunitinib) – US: Patent infringement complaint filed following a Paragraph IV certification: Pfizer Inc. et al. v. [read post]